CLAIMS

1. An aqueous composition comprising a thiazole derivative of the formula (I):

$$R^1 - NH - X - Y - Z$$
 (I)

5 wherein

R1 is acyl;

X is a bivalent residue derived from optionally substituted thiazole;

Y is a bond, lower alkylene, lower alkenylene or -CONH-;

10 and

Z is a group of the formula:

$$N$$
 NH_2 or R^2

wherein R^2 is a group of the formula: -A-B-D-E

wherein A is a bond, lower alkylene, -NH- or -SO₂-;

B is a bond, lower alkylene, -CO- or -O-;

D is a bond, lower alkylene, -NH- or -CH $_2$ NH-, provided that when B is -CO- or -O-, D is not a bond; and

E is optionally protected amino, $-N=CH_2$,

$$\stackrel{N}{\underset{Q}{\longrightarrow}}$$
 or $\stackrel{NH}{\underset{R^3}{\longleftarrow}}$

20 wherein

Q is -S- or -NH-; and

 \mbox{R}^3 is hydrogen, lower alkyl, lower alkylthio or $-\mbox{NH-R}^4$ wherein \mbox{R}^4 is hydrogen, $-\mbox{NH}_2$ or

lower alkyl;

or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alcohol, boric acid or its salt, and water.

5 2. The composition of claim 1, wherein Z of the formula (I) is a group of the formula:

$$\mathbb{R}^2$$

wherein R² is a group of the formula:

(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen, -NH₂ or lower alkyl); -NH₂; -CH₂NH₂; -CH₂ONH₂; -CH₂ON=CH₂;

or a pharmaceutically acceptable salt thereof.

15 3. The composition of claim 2, wherein \mathbb{R}^2 of the formula (I) is a group of the formula:

(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl); -CH₂NH₂; -CH₂ONH₂; -CH₂ON=CH₂;

WO 2005/089755

5

$$-N$$
 , $-N$, NH , NH CH_3 or $-NH$ $S-CH_3$

or a pharmaceutically acceptable salt thereof.

- 4. The composition of any of claims 1 to 3, wherein R¹ of the formula (I) is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.
- 5. The composition of claim 1, wherein the tiazole derivative is
- N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

 $N-\{4-[2-(4-\{[hydrazino(imino)methyl]amino\}phenyl)ethyl]-5-[2-(4-\{[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl)ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl]ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl]ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl]ethyl]-5-[2-(4-[[hydrazino(imino)methyl]amino]phenyl]ethyl]ethyl$

15 [4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]1,3-thiazol-2-yl}acetamide, or

 $N-(4-\{2-[4-(2-$

{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-

20 2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.